BioNTech SE Statistics
Share Statistics
BioNTech SE has 240.39M
shares outstanding. The number of shares has increased by 0.94%
in one year.
| Shares Outstanding | 240.39M |
| Shares Change (YoY) | 0.94% |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | 21.17% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,082 |
| FTD / Avg. Volume | 0.36% |
Short Selling Information
The latest short interest is 4.63M, so 1.93% of the outstanding
shares have been sold short.
| Short Interest | 4.63M |
| Short % of Shares Out | 1.93% |
| Short % of Float | 5.02% |
| Short Ratio (days to cover) | 2.52 |
Valuation Ratios
The PE ratio is -39.73 and the forward
PE ratio is -16.61.
BioNTech SE's PEG ratio is
0.23.
| PE Ratio | -39.73 |
| Forward PE | -16.61 |
| PS Ratio | 9.61 |
| Forward PS | 6 |
| PB Ratio | 1.36 |
| P/FCF Ratio | -108.05 |
| PEG Ratio | 0.23 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for BioNTech SE.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.45,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.45 |
| Quick Ratio | 7.34 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.69 |
| Debt / FCF | -1.04 |
| Interest Coverage | -104.31 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $406,246.31 |
| Profits Per Employee | $-98,242.76 |
| Employee Count | 6,772 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.91 |
Taxes
| Income Tax | -12.4M |
| Effective Tax Rate | 1.83% |
Stock Price Statistics
The stock price has increased by 1.85% in the
last 52 weeks. The beta is 1.36, so BioNTech SE's
price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | 1.85% |
| 50-Day Moving Average | 97.79 |
| 200-Day Moving Average | 107.32 |
| Relative Strength Index (RSI) | 50.47 |
| Average Volume (20 Days) | 1,118,688 |
Income Statement
In the last 12 months, BioNTech SE had revenue of 2.75B
and earned -665.3M
in profits. Earnings per share was -2.77.
| Revenue | 2.75B |
| Gross Profit | 2.21B |
| Operating Income | -1.31B |
| Net Income | -665.3M |
| EBITDA | -367.1M |
| EBIT | -665.1M |
| Earnings Per Share (EPS) | -2.77 |
Full Income StatementBalance Sheet
The company has 9.76B in cash and 254.2M in
debt, giving a net cash position of 9.51B.
| Cash & Cash Equivalents | 9.76B |
| Total Debt | 254.2M |
| Net Cash | 9.51B |
| Retained Earnings | 19.1B |
| Total Assets | 21.18B |
| Working Capital | 14.09B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 207.7M
and capital expenditures -452.3M, giving a free cash flow of -244.6M.
| Operating Cash Flow | 207.7M |
| Capital Expenditures | -452.3M |
| Free Cash Flow | -244.6M |
| FCF Per Share | -1.02 |
Full Cash Flow StatementMargins
Gross margin is 80.32%, with operating and profit margins of -47.77% and -24.18%.
| Gross Margin | 80.32% |
| Operating Margin | -47.77% |
| Pretax Margin | -24.63% |
| Profit Margin | -24.18% |
| EBITDA Margin | -13.34% |
| EBIT Margin | -47.77% |
| FCF Margin | -8.89% |
